RxDoctor Payments Data

Claudia Angulo

Family · Surprise, AZNPI 1851729776

Payments from drug & device makers

$3,320in general payments, 2019–2025

Across 142 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$501
  • Boston Scientific$401
  • Actelion Pharmaceuticals US, Inc.$340
  • Abbott$268
  • Pfizer$210
  • Philips North America LLC$209
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,14695%
  • Education$1745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,320 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$41,621
Medicare patients
207
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$84,968
XareltoRivaroxaban23$27,310
FarxigaDapagliflozin Propanediol16$21,134
Repatha SureclickEvolocumab15$18,275
Metoprolol Succinate237$3,206
Flecainide Acetate39$1,732
Nifedipine ErNifedipine53$1,469
Ranolazine ErRanolazine13$1,468
ClopidogrelClopidogrel Bisulfate106$1,191
Rosuvastatin Calcium66$974
Carvedilol127$906
Atorvastatin Calcium97$893
Amlodipine Besylate135$759
Warfarin Sodium66$746
Amiodarone Hcl26$745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$84,96875 claims
Johnson & JohnsonXarelto$77$27,31023 claims
AstraZenecaFarxiga$41$21,13416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →